Cargando…

One-Year and 18-Month Outcomes in nAMD Patient Eyes Switched to Brolucizumab Alone versus to Brolucizumab Alternating with Other Anti-VEGF Agents

OBJECTIVE: Retrospective, real-world study to evaluate visual acuity (VA), anti-vascular endothelial growth factor (anti-VEGF) injection intervals, and central macular thickness (CMT) in neovascular age-related macular degeneration (nAMD) eyes switched to brolucizumab only or to brolucizumab alterna...

Descripción completa

Detalles Bibliográficos
Autores principales: Coney, Joseph M, McCoy, Jasmyne E, Buxy Sinha, Samriddhi, Sonbolian, Nina, Zhou, Lujia, Hull, Thomas P, Lewis, Shawn A, Miller, David G, Novak, Michael A, Pendergast, Scott D, Pham, Hang, Platt, Sean M, Rao, Llewelyn J, Schartman, Jerome P, Singerman, Lawrence J, Donkor, Richard, Fink, Margaret, Zubricky, Ryan, Karcher, Helene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10680460/
https://www.ncbi.nlm.nih.gov/pubmed/38026599
http://dx.doi.org/10.2147/OPTH.S432957
_version_ 1785150721164836864
author Coney, Joseph M
McCoy, Jasmyne E
Buxy Sinha, Samriddhi
Sonbolian, Nina
Zhou, Lujia
Hull, Thomas P
Lewis, Shawn A
Miller, David G
Novak, Michael A
Pendergast, Scott D
Pham, Hang
Platt, Sean M
Rao, Llewelyn J
Schartman, Jerome P
Singerman, Lawrence J
Donkor, Richard
Fink, Margaret
Zubricky, Ryan
Karcher, Helene
author_facet Coney, Joseph M
McCoy, Jasmyne E
Buxy Sinha, Samriddhi
Sonbolian, Nina
Zhou, Lujia
Hull, Thomas P
Lewis, Shawn A
Miller, David G
Novak, Michael A
Pendergast, Scott D
Pham, Hang
Platt, Sean M
Rao, Llewelyn J
Schartman, Jerome P
Singerman, Lawrence J
Donkor, Richard
Fink, Margaret
Zubricky, Ryan
Karcher, Helene
author_sort Coney, Joseph M
collection PubMed
description OBJECTIVE: Retrospective, real-world study to evaluate visual acuity (VA), anti-vascular endothelial growth factor (anti-VEGF) injection intervals, and central macular thickness (CMT) in neovascular age-related macular degeneration (nAMD) eyes switched to brolucizumab only or to brolucizumab alternating with another anti-VEGF. METHODS: The overall study population comprised eyes that were given ≥1 brolucizumab injection between 1 October 2019 and 30 November 2021. The brolucizumab-only (BRO) cohort consisted of prior anti-VEGF-treated eyes treated exclusively with ≥3 brolucizumab injections over ≥12 or ≥18 months; the alternating brolucizumab (ALT) cohort comprised prior anti-VEGF-treated eyes treated with ≥2 brolucizumab injections and ≥1 other anti-VEGF over ≥12 or ≥18 months. RESULTS: A total of 482 eyes received ≥1 brolucizumab injection during the study period. Mean VA changes from baseline were −1.1±15.1 letters (BRO cohort; n = 174) and 1.3±13.0 letters (ALT cohort; n = 47) at Month 12, and 0.0±13.5 letters (BRO cohort; n = 95) and −7.3±17.2 letters (ALT cohort; n = 29) at Month 18. Mean changes in injection intervals were +26.9±48.1 days (BRO cohort) and +11.1±17.3 days (ALT cohort) at Month 12 and +36.3±52.3 days (BRO cohort) and +14.0±19.9 days (ALT cohort) at Month 18. Mean changes in CMT were −35.2±108.1 μm (BRO cohort) and −31.5±91.2 μm (ALT cohort) at Month 12 and −38.9±75.0 μm (BRO cohort) and −9.0±59.9 μm (ALT cohort) at Month 18. Intraocular inflammation-related adverse events were recorded in 22/482 (4.6%) eyes. CONCLUSION: Treatment with either brolucizumab alone or brolucizumab alternating with another anti-VEGF can preserve vision, reduce CMT, and extend anti-VEGF injection intervals in patients with nAMD.
format Online
Article
Text
id pubmed-10680460
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-106804602023-11-23 One-Year and 18-Month Outcomes in nAMD Patient Eyes Switched to Brolucizumab Alone versus to Brolucizumab Alternating with Other Anti-VEGF Agents Coney, Joseph M McCoy, Jasmyne E Buxy Sinha, Samriddhi Sonbolian, Nina Zhou, Lujia Hull, Thomas P Lewis, Shawn A Miller, David G Novak, Michael A Pendergast, Scott D Pham, Hang Platt, Sean M Rao, Llewelyn J Schartman, Jerome P Singerman, Lawrence J Donkor, Richard Fink, Margaret Zubricky, Ryan Karcher, Helene Clin Ophthalmol Original Research OBJECTIVE: Retrospective, real-world study to evaluate visual acuity (VA), anti-vascular endothelial growth factor (anti-VEGF) injection intervals, and central macular thickness (CMT) in neovascular age-related macular degeneration (nAMD) eyes switched to brolucizumab only or to brolucizumab alternating with another anti-VEGF. METHODS: The overall study population comprised eyes that were given ≥1 brolucizumab injection between 1 October 2019 and 30 November 2021. The brolucizumab-only (BRO) cohort consisted of prior anti-VEGF-treated eyes treated exclusively with ≥3 brolucizumab injections over ≥12 or ≥18 months; the alternating brolucizumab (ALT) cohort comprised prior anti-VEGF-treated eyes treated with ≥2 brolucizumab injections and ≥1 other anti-VEGF over ≥12 or ≥18 months. RESULTS: A total of 482 eyes received ≥1 brolucizumab injection during the study period. Mean VA changes from baseline were −1.1±15.1 letters (BRO cohort; n = 174) and 1.3±13.0 letters (ALT cohort; n = 47) at Month 12, and 0.0±13.5 letters (BRO cohort; n = 95) and −7.3±17.2 letters (ALT cohort; n = 29) at Month 18. Mean changes in injection intervals were +26.9±48.1 days (BRO cohort) and +11.1±17.3 days (ALT cohort) at Month 12 and +36.3±52.3 days (BRO cohort) and +14.0±19.9 days (ALT cohort) at Month 18. Mean changes in CMT were −35.2±108.1 μm (BRO cohort) and −31.5±91.2 μm (ALT cohort) at Month 12 and −38.9±75.0 μm (BRO cohort) and −9.0±59.9 μm (ALT cohort) at Month 18. Intraocular inflammation-related adverse events were recorded in 22/482 (4.6%) eyes. CONCLUSION: Treatment with either brolucizumab alone or brolucizumab alternating with another anti-VEGF can preserve vision, reduce CMT, and extend anti-VEGF injection intervals in patients with nAMD. Dove 2023-11-23 /pmc/articles/PMC10680460/ /pubmed/38026599 http://dx.doi.org/10.2147/OPTH.S432957 Text en © 2023 Coney et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Coney, Joseph M
McCoy, Jasmyne E
Buxy Sinha, Samriddhi
Sonbolian, Nina
Zhou, Lujia
Hull, Thomas P
Lewis, Shawn A
Miller, David G
Novak, Michael A
Pendergast, Scott D
Pham, Hang
Platt, Sean M
Rao, Llewelyn J
Schartman, Jerome P
Singerman, Lawrence J
Donkor, Richard
Fink, Margaret
Zubricky, Ryan
Karcher, Helene
One-Year and 18-Month Outcomes in nAMD Patient Eyes Switched to Brolucizumab Alone versus to Brolucizumab Alternating with Other Anti-VEGF Agents
title One-Year and 18-Month Outcomes in nAMD Patient Eyes Switched to Brolucizumab Alone versus to Brolucizumab Alternating with Other Anti-VEGF Agents
title_full One-Year and 18-Month Outcomes in nAMD Patient Eyes Switched to Brolucizumab Alone versus to Brolucizumab Alternating with Other Anti-VEGF Agents
title_fullStr One-Year and 18-Month Outcomes in nAMD Patient Eyes Switched to Brolucizumab Alone versus to Brolucizumab Alternating with Other Anti-VEGF Agents
title_full_unstemmed One-Year and 18-Month Outcomes in nAMD Patient Eyes Switched to Brolucizumab Alone versus to Brolucizumab Alternating with Other Anti-VEGF Agents
title_short One-Year and 18-Month Outcomes in nAMD Patient Eyes Switched to Brolucizumab Alone versus to Brolucizumab Alternating with Other Anti-VEGF Agents
title_sort one-year and 18-month outcomes in namd patient eyes switched to brolucizumab alone versus to brolucizumab alternating with other anti-vegf agents
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10680460/
https://www.ncbi.nlm.nih.gov/pubmed/38026599
http://dx.doi.org/10.2147/OPTH.S432957
work_keys_str_mv AT coneyjosephm oneyearand18monthoutcomesinnamdpatienteyesswitchedtobrolucizumabaloneversustobrolucizumabalternatingwithotherantivegfagents
AT mccoyjasmynee oneyearand18monthoutcomesinnamdpatienteyesswitchedtobrolucizumabaloneversustobrolucizumabalternatingwithotherantivegfagents
AT buxysinhasamriddhi oneyearand18monthoutcomesinnamdpatienteyesswitchedtobrolucizumabaloneversustobrolucizumabalternatingwithotherantivegfagents
AT sonboliannina oneyearand18monthoutcomesinnamdpatienteyesswitchedtobrolucizumabaloneversustobrolucizumabalternatingwithotherantivegfagents
AT zhoulujia oneyearand18monthoutcomesinnamdpatienteyesswitchedtobrolucizumabaloneversustobrolucizumabalternatingwithotherantivegfagents
AT hullthomasp oneyearand18monthoutcomesinnamdpatienteyesswitchedtobrolucizumabaloneversustobrolucizumabalternatingwithotherantivegfagents
AT lewisshawna oneyearand18monthoutcomesinnamdpatienteyesswitchedtobrolucizumabaloneversustobrolucizumabalternatingwithotherantivegfagents
AT millerdavidg oneyearand18monthoutcomesinnamdpatienteyesswitchedtobrolucizumabaloneversustobrolucizumabalternatingwithotherantivegfagents
AT novakmichaela oneyearand18monthoutcomesinnamdpatienteyesswitchedtobrolucizumabaloneversustobrolucizumabalternatingwithotherantivegfagents
AT pendergastscottd oneyearand18monthoutcomesinnamdpatienteyesswitchedtobrolucizumabaloneversustobrolucizumabalternatingwithotherantivegfagents
AT phamhang oneyearand18monthoutcomesinnamdpatienteyesswitchedtobrolucizumabaloneversustobrolucizumabalternatingwithotherantivegfagents
AT plattseanm oneyearand18monthoutcomesinnamdpatienteyesswitchedtobrolucizumabaloneversustobrolucizumabalternatingwithotherantivegfagents
AT raollewelynj oneyearand18monthoutcomesinnamdpatienteyesswitchedtobrolucizumabaloneversustobrolucizumabalternatingwithotherantivegfagents
AT schartmanjeromep oneyearand18monthoutcomesinnamdpatienteyesswitchedtobrolucizumabaloneversustobrolucizumabalternatingwithotherantivegfagents
AT singermanlawrencej oneyearand18monthoutcomesinnamdpatienteyesswitchedtobrolucizumabaloneversustobrolucizumabalternatingwithotherantivegfagents
AT donkorrichard oneyearand18monthoutcomesinnamdpatienteyesswitchedtobrolucizumabaloneversustobrolucizumabalternatingwithotherantivegfagents
AT finkmargaret oneyearand18monthoutcomesinnamdpatienteyesswitchedtobrolucizumabaloneversustobrolucizumabalternatingwithotherantivegfagents
AT zubrickyryan oneyearand18monthoutcomesinnamdpatienteyesswitchedtobrolucizumabaloneversustobrolucizumabalternatingwithotherantivegfagents
AT karcherhelene oneyearand18monthoutcomesinnamdpatienteyesswitchedtobrolucizumabaloneversustobrolucizumabalternatingwithotherantivegfagents